Atiprimod Completed Phase 2 Trials for Neuroendocrine Carcinomas Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00663429Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma
NCT00388063Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma